# Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission

> **NCT00209300** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 362 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Pentasa

## Key facts

- **NCT ID:** NCT00209300
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-05
- **Final completion:** 2007-06
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209300, "Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00209300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*